News

Under the terms of the agreement, GSK will use Covance Xcellerate® Monitoring, Xcellerate Insights, and Xcellerate Clinical Data Hub solutions in a software-as-a-service (SaaS) model. Covance technology products

ZTlido includes non-aqueous adhesive material containing 1.8% lidocaine, which will be applied to a non-woven polyester felt backing and covered with a polyethylene terephthalate (PET) film release liner.

The new independent biotech company, Viela Bio, will get six molecules from MedImmune's early-stage inflammation and autoimmunity programs. Viela Bio, which will get a funding of up to $250m, will

Ozanimod is being developed for the treatment of patients with relapsing forms of multiple sclerosis. Ozanimod is an oral and selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor

If approved, KP-470 will represent a novel drug with an alternate mechanism of action in the topical treatment of the disease. Under the terms of the licensing agreement,

The round was led by New Enterprise Associates, with participation from 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital,

The drug is a bispecific antibody that targets the factor IXa- and factor X proteins. Hemlibra has been designed to bind the two proteins, which are needed to

The Phase 1 clinical trial is a randomized, observer-blinded, placebo-controlled, single center study. This study, in approximately 65 healthy adults, will investigate two dose levels of VLA1601 when

Lusutrombopag (S-888711) is an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist. In the US, Shionogi is seeking FDA approval of lusutrombopag for the treatment of thrombocytopenia